Acute ischemic stroke is caused by a blockage of blood flow to the brain that interrupts nutrient and oxygen delivery to brain cells. With rapid advances in stroke treatment technologies such as mechanical thrombectomy and neurovascular stents, medical professionals are now more capable of reversing or limiting neurological damage in AIS patients.
The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 9211.99 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of advanced stroke treatment procedures is a major trend spurring the growth of the AIS market. Procedures such as mechanical thrombectomy that use catheters and stents to remove blood clots have significantly higher recanalization and reperfusion rates compared to conventional medications. For example, a recent clinical trial showed that thrombectomy achieved reperfusion in ~70% of patients compared to just ~30% with medications alone. With better clinical outcomes, mechanical thrombectomy is becoming the standard of care for many eligible AIS patients presenting within 6 hours of symptom onset. This rising demand for thrombectomy devices and stents is expected to drive lucrative growth for companies in the AIS market over the forecast period.
SWOT Analysis
Strength: AIS therapies have strong clinical evidence to support their efficacy and safety profiles. Growing adoption of telestroke helps improve access to care.
Weakness: High cost burden of treatment and long-term care for stroke patients poses significant challenge. Lack of trained stroke specialists in many regions.
Opportunity: Rising geriatric population susceptible to strokes increases the market potential. Developing markets in Asia Pacific yet to be tapped to their full potential.
Threats: Stiff competition from alternative treatment options. Reimbursement uncertainties hinders market growth.
Key Takeaways
The Global Acute Ischemic Stroke Market Size is expected to witness high growth. The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 9211.99 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.
Regional analysis
North America currently dominates the global AIS market due to presence of highly developed healthcare infrastructure and robust reimbursement framework supporting drug development. Asia Pacific market is expected to witness fastest growth owing to rising healthcare expenditure, emergence of local players and growing medical tourism.
Key players operating in the AIS market are B. Braun Melsungen AG, Baxter, BD, Johnson & Johnson Private Limited, Stryker Corp., Integra LifeSciences Corporation, Medtronic plc, Acera Surgical, Inc., Anthrex, Inc., Acelity L.P. Inc., Biorez, Aroa Biosurgery Limited, Misonix, Inc., Ortho Regenerative Technologies Inc., AlloSource, Boston Scientific Corporation, TEIJIN LIMITED, and Smith+Nephew, CONMED Corporation.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.